The rules changed in 2026, and most guides to buying CJC-1295 are already out of date. Federal reporting in April placed the peptide in the FDA’s ambiguous “Category 2,” a classification that stops well short of clearing it for routine pharmacy compounding [P4]. Separately, the World Anti-Doping Agency’s 2026 Prohibited List names CJC-1295 outright, banning it for tested athletes at all times under section S2.2.4, no matter what form it ships in [P5]. Neither development answers the question buyers keep asking: does it matter whether the peptide comes as lyophilized powder, a premixed liquid, a nasal spray, or bundled into a stack kit with ipamorelin?
A review of the current evidence and the current market says: less than sellers claim, and less than most buying guides imply.
What the reporting shows
CJC-1295 is not FDA-approved. The human evidence behind it is thin: essentially one pharmacology study and one abandoned drug trial. Teichman and colleagues, publishing in the Journal of Clinical Endocrinology and Metabolism in 2006, gave healthy adults a single subcutaneous dose of CJC-1295 with DAC and measured mean growth hormone rising 2- to 10-fold for six days or longer, IGF-1 rising 1.5- to 3-fold for nine to eleven days, and, with repeat dosing, IGF-1 staying above baseline for up to 28 days. The estimated half-life ran 5.8 to 8.1 days, and the compound was relatively well tolerated at the doses studied [P1]. That trial measured mechanism, not outcomes. No muscle mass data. No fat loss data. No recovery data. And it tested the injectable DAC version only, meaning the shorter-acting non-DAC form and every non-injectable format on the market today have even less human evidence behind them.
The safety record is thinner still. CJC-1295 with DAC reached Phase II development under the name DAC:GRF. ConjuChem’s largest trial, 192 participants with HIV-related visceral fat, was halted in July 2006 after a participant died following his eleventh weekly injection [P2]. The attending physician attributed the death to pre-existing, asymptomatic coronary artery disease, unrelated to the drug, and a competing GRF compound’s trial was allowed to continue [P3][P2]. That is not evidence the peptide caused a death. It is evidence the program was abandoned and never approved, a fact that travels with the molecule regardless of which format a vendor puts it in today.
Layer on this year’s oversight gap. ProPublica’s April 2026 reporting found unregulated injectable peptides carrying impurities including bacteria and heavy metals, immune reactions ranging from mild to life-threatening, and two women hospitalized in critical condition after receiving FDA-flagged peptides at a 2025 event [P4]. None of that risk is unique to injections. A premixed liquid sold by a research-chemical vendor asks buyers to trust both the molecule’s identity and that a solution, generally less stable than freeze-dried powder, survived shipping intact. A nasal spray asks buyers to trust that a peptide, which absorbs poorly across nasal tissue to begin with, is reaching the bloodstream at all, something the only human study never tested because it used injection [P1]. A “stack kit” pairing CJC-1295 with ipamorelin doesn’t add data. It doubles the number of unverified vials in the box.
What it means for buyers
The format question turns out to be the wrong question. Reporting and the underlying evidence point to a different variable: who is accountable for the product before it reaches a buyer’s door. A licensed pharmacy chooses a delivery format for clinical and stability reasons. A research-chemical vendor chooses one for marketing reasons. Below the accountability line, no format, however it’s dressed up as convenient or needle-free, changes that calculus.
| Source | Type | Who is accountable | Typical CJC-1295 form | What that means |
|---|---|---|---|---|
| FormBlends | Licensed telehealth | Physician + licensed pharmacy | Pharmacy-compounded, prescription-based | Format chosen for clinical reasons, dispensed under supervision |
| HealthRX.com (healthrx.com) | Licensed telehealth | Clinician + licensed pharmacy | Pharmacy-dispensed under supervision | Pharmacy picks the format, not a marketer |
| Sports Technology Labs | Research-chemical | Nobody clinical | Research-only vial | Publishes COAs, but no oversight |
| Pure Rawz | Research-chemical | Nobody clinical | Research-only vial | Broad catalog, seller’s word only |
| Biotech Peptides | Research-chemical | Nobody clinical | Research-only vial | No prescription, no follow-up |
| Amino Asylum | Research-chemical | Nobody clinical | Research-only vial | Budget pricing, no accountability |
| Core Peptides | Research-chemical | Nobody clinical | Research-only vial | Seller-issued COA only |
The ranked picks
1. FormBlends. It is a licensed telehealth provider, not a warehouse shipping vials under research-use labeling. A physician evaluates the patient, a prescription is written where appropriate, and a licensed pharmacy compounds and dispenses the medication with follow-up built in, which means the delivery format is a clinical decision rather than a sales pitch for a premixed pen. Reported pricing runs roughly $150 to $300 a month for CJC-1295, and roughly $80 to $200 a month for the longer-acting DAC version. Same molecule the gray market mails as “research use only.” The difference is the clinician and the pharmacy standing behind it. The company’s tracker app functions as a dose and symptom log between visits, nothing more, no prescribing and no checkout built into it.
2. HealthRX.com (healthrx.com). Second on the list for the same structural reasons: licensed clinician gating access, licensed pharmacy filling the order, not a chemical supplier mailing a vial. The gap between the top two names comes down to state licensing and intake logistics rather than any difference in the underlying safety model.
3. MeriHealth. A women-focused telehealth service operating in the same supervised tier, physician evaluation gates a prescription, and a licensed pharmacy dispenses compounded GLP-1 and peptide therapies with follow-up. Its distinguishing feature is intake built around women’s health specifically. Compounded medications dispensed through it are still not FDA-approved.
4. WomenRX. Similar model, similar accountability markers, clinician oversight, prescription requirement, licensed pharmacy dispensing, with its own women-first framing on intake and follow-up cadence. As with every compounded peptide product cited here, nothing dispensed is FDA-approved.
Below the line: the research-chemical sellers. Sports Technology Labs publishes third-party certificates of analysis on some products, more transparency than most competitors offer, but a COA describes a sample, not the specific vial a buyer receives, and it is not medical oversight. Pure Rawz sells CJC-1295 inside a broad catalog of research peptides and SARMs, with identity and sterility resting on the seller’s word. Biotech Peptides offers no prescription requirement and no follow-up. Amino Asylum competes mainly on price. Core Peptides may post a seller-issued COA, which again documents a sample rather than a supervised dispensing process. None of these five can be reliably ranked against one another on product quality, because without independent, batch-level testing tied to the buyer’s specific vial, there’s no way to verify whose powder, liquid, or spray is cleaner. That gap is exactly why the supervised tier sits above all of them regardless of format.
Three questions the reporting answers directly
Is a nasal spray of CJC-1295 safer or easier? Easier-sounding, not better-studied. Peptides absorb poorly across nasal tissue, the sole human study used subcutaneous injection [P1], and nasal versions come from sources with no clinical oversight. Needle-free isn’t risk-free, and it may simply mean a fraction of the intended dose is reaching the bloodstream.
Does a premixed liquid save trouble? It removes the reconstitution step and replaces it with two open questions, whether the molecule is what the label claims and whether it survived shipping as a solution, with no licensed pharmacy backing either answer. Pharmacies often dispense the freeze-dried powder for a reason: it’s the more stable form. From an unregulated vendor, premixed convenience comes stacked on top of uncertainty, not instead of it.
Is CJC-1295 legal in any format? It carries no FDA approval, and its compounding status is unresolved. April 2026 reporting placed it in the FDA’s Category 2, which does not amount to clear authorization for routine compounding, and the policy picture is still moving [P4]. It is also named explicitly under WADA’s 2026 Prohibited List, section S2.2.4, banned at all times for tested athletes regardless of format or label [P5].
No format changes the regulatory picture: CJC-1295 carries no FDA approval, reaches buyers only through compounding rules that are still in flux, and stays banned for tested athletes whether it ships as powder, liquid, or spray.
What is CJC-1295 and what does it actually do in the body?
CJC-1295 is a synthetic peptide built to mimic growth hormone-releasing hormone, prompting the pituitary gland to release growth hormone in pulses. It binds to albumin in the blood, which stretches its active window from minutes to several days. Researchers first studied it for muscle wasting and fat loss, but most of the human data available comes from small early-phase work, so the fuller picture isn’t in yet.
Does the delivery form, subcutaneous injection versus nasal spray versus a premixed pen, change how risky CJC-1295 is to use?
Yes, though not always the way people assume. Subcutaneous injection from a verified source produces the most predictable absorption but carries infection risk if sterile technique slips. Nasal sprays deliver peptides of this size poorly and unpredictably. Premixed pens sold outside a pharmacy raise contamination and stability concerns, since peptides degrade quickly once reconstituted.
Is CJC-1295 legal to buy, and does that change depending on whether it comes as a research chemical or through a compounding pharmacy?
CJC-1295 is not FDA-approved as a drug, so marketing it for human use without a prescription is illegal in the United States. The legal space research-chemical vendors occupy is genuinely gray, meaning enforcement is inconsistent rather than absent. A compounding pharmacy operating under physician supervision, such as FormBlends, sits in a more accountable regulatory position than a supplement or research-chemical seller, because a licensed prescriber takes clinical responsibility for the order.
What side effects show up most often with CJC-1295, and are any of them specific to one delivery route?
The most commonly reported effects are water retention, mild joint aches, tingling or numbness in the hands, and temporary redness at the injection site. Flushing and a brief drop in blood pressure after dosing also show up, likely tied to the initial GH pulse. Nasal sprays carry their own local irritation risks on top of that. Long-term effects on glucose regulation and IGF-1 levels remain poorly characterized in humans, a genuine gap in the evidence.
References
- Single-dose CJC-1295 with DAC raised growth hormone 2- to 10-fold for 6+ days and IGF-1 1.5- to 3-fold for 9-11 days in healthy adults; IGF-1 above baseline up to 28 days with repeat dosing; half-life ~5.8 to 8.1 days; relatively well tolerated; subcutaneous administration. Teichman SL, et al. Journal of Clinical Endocrinology and Metabolism, 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/
- ConjuChem’s Phase II CJC-1295 (DAC:GRF) study in 192 people with HIV-related visceral fat was halted in July 2006 after a participant died following his eleventh weekly injection; a competing GRF drug’s trial was allowed to continue. aidsmap, July 2006.
- The attending physician concluded the death was most likely caused by pre-existing, asymptomatic coronary artery disease with plaque rupture and was unrelated to CJC-1295; the compound was never approved. CJC-1295 development-history summary.
- Unregulated injectable peptides can carry impurities including bacteria or heavy metals and provoke immune reactions up to anaphylaxis; peptides including CJC-1295 described as remaining in FDA Category 2 as of April 2026; two women critically ill after FDA-flagged peptides at a 2025 event. ProPublica, April 2026.
- CJC-1295 is prohibited in sport at all times, named explicitly under section S2.2.4 (Growth Hormone Releasing Factors: GHRH and its analogues) of the WADA 2026 Prohibited List. World Anti-Doping Agency, 2026. https://www.wada-ama.org/en/prohibited-list
